<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04723615</url>
  </required_header>
  <id_info>
    <org_study_id>2020/469</org_study_id>
    <nct_id>NCT04723615</nct_id>
  </id_info>
  <brief_title>Orebro Musculoskeletal Screening Questionnaire-12</brief_title>
  <official_title>Evaluation of Turkish Validity, Reliability and Practicality of Örebro Musculoskeletal System Screening Questionnaire-12</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Afyonkarahisar Health Sciences University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Afyonkarahisar Health Sciences University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research is a study with methodological design. The validity, reliability and&#xD;
      practicality of the Örebro Musculoskeletal System Screening Questionnaire-12 will be&#xD;
      investigated. In this context, a questionnaire will be applied to the participants to take&#xD;
      part in the study after the translation process is completed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Musculoskeletal disorders are quite common in developed and developing countries.&#xD;
      Musculoskeletal disorders cause economic burdens in the individual and social field. In&#xD;
      addition, getting reports is one of the main causes of reduced productivity and work&#xD;
      disability. Therefore, inexpensive and easily applicable screening questionnaires are needed&#xD;
      to determine the patient population with high risk musculoskeletal disorders. The Örebro&#xD;
      Musculoskeletal Screening Questionnaire is a practical questionnaire that can evaluate&#xD;
      musculoskeletal disorders and is tailored to the WHO-ICF themes. For this reason, the aim of&#xD;
      the study is to translate the Örebro Musculoskeletal System Survey-12 into Turkish&#xD;
      intercultural translation and to investigate the construct validity, reliability and&#xD;
      practicality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2020</start_date>
  <completion_date type="Anticipated">December 18, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 18, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Orebro Musculoskeletal Screening Questionnaire-12</measure>
    <time_frame>10 minutes</time_frame>
    <description>It is a 12-item self-report questionnaire that aims to estimate a wide range of outcomes (severity of the problem, functional impairment, reporting status, cost and recovery time) in patients with acute and subacute work injury presenting with musculoskeletal pain involving the spine, upper and lower extremities.</description>
  </primary_outcome>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Musculoskeletal Injury</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Orebro Musculoskeletal Screening Questionnaire-12</intervention_name>
    <description>It is a 12-item self-report questionnaire that aims to estimate the severity of the problem, functional impairment, reporting status, cost and recovery time in musculoskeletal problems.</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Visual Analog Scale</intervention_name>
    <description>A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured.</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>The Tampa Scale of Kinesiophobia</intervention_name>
    <description>The Tampa Scale of Kinesiophobia that was developed in 1990 is a 17 item scale originally developed to measure the fear of movement related to chronic lower back pain.</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Short Form-12 (SF-12)</intervention_name>
    <description>The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be contacted via Google forms after the entire translation process of the&#xD;
        questionnaire is completed. Participants will be 18-65 years and have any musculoskeletal&#xD;
        problems (spine, upper or lower extremities).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having any musculoskeletal problems (spine, upper or lower extremities)&#xD;
&#xD;
          -  Being in the age range of 18-65&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Having of red flag signs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>EMEL TAŞVURAN HORATA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Afyonkarahisar Health Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>EMEL TAŞVURAN HORATA</last_name>
    <phone>+905547759663</phone>
    <email>ethorata@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emel Taşvuran Horata</name>
      <address>
        <city>Afyonkarahisar</city>
        <zip>03030</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>EMEL TAŞVURAN HORATA</last_name>
      <phone>05547759663</phone>
      <email>ethorata@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Suat EREL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gözde YAGCI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>EMEL TAŞVURAN HORATA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philip GABEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 17, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Afyonkarahisar Health Sciences University</investigator_affiliation>
    <investigator_full_name>Emel Taşvuran Horata</investigator_full_name>
    <investigator_title>PhD; Assistant Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

